Publication | Open Access

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

Second-line TreatmentOncologyMetronomic TherapyDocetaxel Versus DocetaxelClinical TrialsBronchial NeoplasmPharmacotherapyCancer TreatmentMedicineRadiation OncologyLung CancerRadiologyHealth Sciences